Scientific Advisors

pick1

Julia Levy, PhD

As co-inventor of Visudyne and co-founder of QLT, Dr. Levy served in several key senior positions at the company including Chief Scientific Officer as well as President and CEO. Under Dr. Levy’s leadership, QLT recorded the strongest period of growth in the company’s history and earned a reputation for achieving milestones, including FDA approval for Visudyne to treat age-related macular degeneration, the commonest cause of severe vision loss in the elderly. Dr. Levy has earned numerous awards and honours including an appointment as an Officer of the Order of Canada, the Female Entrepreneur of the Year for International Business, Pacific Canada Entrepreneur of the Year and the Future of Vision Award from the Foundation Fighting Blindness. In 2002 she received, along with Dr. David Dolphin, the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. In her honour, the Julia G. Levy Professorship in Ophthalmology Chair was created at Johns Hopkins Hospital Wilmer Eye Institute in 2004, the same year she was awarded the Lifetime Achievement Award from the BC Biotechnology Association. In 2009, the province of British Columbia permanently endowed the Julia Levy B.C. Leadership Chair in Macular Research at the University of British Columbia (U.B.C.) in partnership with U.B.C. and QLT.

David Mullins_web

David W. Mullins, PhD

Dr. Mullins is Assistant Professor in the Geisel School of Medicine at Dartmouth College (Hanover, NH), with appointments in the Departments of Medical Education and Microbiology/Immunology. Dr. Mullins is also a Member of the Immunology and Cancer Immunotherapy Research Program at Dartmouth’s Norris Cotton Cancer Center (Lebanon, New Hampshire).

Dr. Mullins is a recognized expert in cancer immunobiology and immune cell trafficking to tumours. He received a PhD in Immunology from Virginia Polytechnic Institute and State University (Virginia Tech), studying pharmacologic approaches to reverse the immunosuppressive activity of tumour-associated macrophages He completed advanced training in tumour immunology and cancer immunotherapy at the University of Virginia, where his work demonstrated tissue-specific targeting of vaccine-induced lymphocytes. Through translational research and clinical trials, he continues to investigate and develop novel strategies for immune therapy of metastatic cancers.

Dr. Mullins is an active member of the American Association of Immunologists, serving on the Committee for Immunology Education. He also serves as a reviewer for leading immunology journals, including the Journal of Immunology, Cancer Research, Clinical Cancer Research, and the Journal of Immunotherapy.

pick2

R.E.W. Hancock, PhD, OC, OBC, FRSC

Dr. Hancock is a Professor of Microbiology & Immunology at UBC and is a Canada Research Chair holder. He was the founding Scientific Director of the Canadian Bacterial Diseases Network and currently heads the UBC Centre for Microbial Diseases and Immunity Research. His research interests include antibiotic uptake and resistance, systems biology and the development of small cationic peptides as novel antimicrobials and modulators of innate immunity. He has published more than 480 papers and reviews, is an ISI highly cited author in Microbiology with more than 20,000 citations, and has 36 patents awarded. He has won many awards, including the Aventis Pharmaceuticals Award in 2003 and Canada’s three top prizes for Health Research. In 2001 he was inducted as an Officer of the Order of Canada. He is co-founder of Inimex Pharmaceuticals Inc., Migenix Inc., and the Centre for Drug Research and Development, and has served as a Scientific Advisory Board member or consultant with 27 biotech and pharmaceutical companies. Dr. Hancock is a key participant on two large multinational Grand Challenges in Global Health Research grants aimed at delivering antimicrobial therapies and effective vaccines to developing countries.

pick3

Kent R. Van Kampen, DVM, PhD

Currently CEO of The Van Kampen Group, Dr. Van Kampen has held leadership roles at several biotechnology companies including COO of Vaxin Inc. and CEO at Virogenetics, a Division of Aventis Pasteur, which was the largest vaccine company in the world. While leading Virogenetics, the division created multiple recombinant vaccines that are currently licensed in the veterinary market. Dr. Van Kampen brings a wealth of experience in the field of vaccinology, especially in research, development and commercialization. Earlier in his career, Dr. Van Kampen was the Department Head of Veterinary Sciences at Utah State University and Director of Physiological Research at Medtronic. He is a Diplomate of the American College of Veterinary Pathologists. He serves on the Boards of SVK Laboratories, HMV Corp., ImmunoMed Corp., Cognative Engineering and The Van Kampen Group Inc.

pick4

David G. Barnes, MD

Dr. Barnes is an entrepreneurial physician-scientist who has partnered in the successful launch of several bio-medical research and development companies. Currently, Dr. Barnes holds multiple executive officer and board level positions in a range of companies from small biotech start-ups to large public multinationals (e.g. Nometics Inc. (Ottawa); PharmaGap Inc. (Ottawa); Cortria Corporation (Boston), CSL Behring Inc. (multi-national). Dr. Barnes is a former clinical evaluator, Biologics and Genetic Therapies Directorate and former Head, Biotechnology Products Surveillance Unit, Marketed Health Products Directorate, Health Canada.

Dieter Kabelitz MD

Dieter Kabelitz studied medicine in Freiburg and Munich, Germany. He was a post-doc in Uppsala/Sweden and at Rockefeller University, New York. In 1988, he was appointed Associate Professor for Cellular Immunology at the University of Heidelberg. From 1992 to 1999 he was Head of the Department of Immunology at the Paul-Ehrlich Institute in Langen. Since 1999 he is a full professor at the University of Kiel and Director of the Institute of Immunology. His scientific expertise is in the field of functional characterization of human T cells, specifically γδT cells. Current projects aim to explore the potential of human γδT cells for the immunotherapy of cancer. Dieter Kabelitz was chairman of the DFG-funded Collaborative Research Center (SFB) 415  “Specificity and Pathophysiology of Signal Transduction Pathways” at Kiel University and is currently a member of the Steering Committee of the DFG-funded Cluster of Excellence “Inflammation-at-Interfaces”. He was president of the German Society for Immunology (DGf)I in 2011/12 and is a Council member of the International Union of Immunological Societies (IUIS).

Past events:


Past events: